Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-08-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于健帆转债回售的第四次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the conditional repurchase (回售) of convertible bonds (可转债) issued by 健帆生物科技集团股份有限公司. It includes specific bond codes, repurchase prices, dates for repurchase application, payment schedules, and procedural details. The text is a formal public notice about the bond repurchase event, including risk warnings and regulatory compliance references. It does not contain financial statements, audit results, or management discussion and analysis. It is not a report but an announcement of a financing-related event concerning bond repurchase terms and procedures. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3336 characters, which is consistent with an announcement rather than a full report.
2025-08-07 Chinese
关于健帆转债回售的第三次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the conditional repurchase (回售) of convertible bonds (可转债) issued by 健帆生物科技集团股份有限公司. It includes specific bond codes, repurchase prices, dates for repurchase application periods, payment schedules, and risk warnings. The document is a formal public notice about the bond repurchase process and related procedures, not a financial report or earnings release. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a regulatory certification or legal proceeding update. The content fits best with a Capital/Financing Update (CAP) as it concerns financing activities related to convertible bonds and their repurchase terms and conditions. The document length is 3336 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is Capital/Financing Update (CAP).
2025-08-06 Chinese
关于健帆转债回售的第二次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the conditional repurchase (回售) of convertible bonds (可转债) issued by 健帆生物科技集团股份有限公司. It includes specific bond codes, repurchase prices, repurchase conditions, timelines for repurchase application, payment dates, and procedural details. The document is not a financial report, earnings release, or management discussion but a formal notification about bond repurchase rights and procedures. It is a regulatory announcement related to capital/financing activities, specifically about bond repurchase rights and procedures. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3339 characters, which is consistent with a detailed announcement rather than a full report.
2025-08-05 Chinese
关于健帆转债回售的第一次提示性公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the conditional repurchase (回售) of convertible bonds (可转债) issued by 健帆生物科技集团股份有限公司. It includes specific bond codes, repurchase prices, dates for repurchase application, payment schedules, and procedural details. The text references regulatory requirements and disclosure obligations related to convertible bond repurchase rights. It is not a financial report, earnings release, or management discussion but a formal notification about bond repurchase rights and procedures. This fits the category of Capital/Financing Update (CAP), as it concerns financing instruments and capital structure changes related to convertible bonds.
2025-08-04 Chinese
国浩律师（深圳）事务所关于健帆生物科技集团股份有限公司可转换公司债券回售之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the conditional repurchase (回售) of convertible bonds issued by the company. It references relevant laws, regulatory approvals, board and shareholder meetings approving the bond issuance, and the terms under which bondholders can sell back their bonds to the company. The document is a standalone legal opinion related to a specific financing event (convertible bond repurchase) and does not contain financial statements or earnings data. It is not an announcement of a report publication but a detailed legal opinion on a capital/financing matter. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive legal analysis and details about the financing event, not just a brief announcement, so it is not RPA or RNS. Confidence is high due to clear focus on convertible bond repurchase legal opinion and regulatory compliance.
2025-08-01 Chinese
中航证券有限公司关于健帆生物科技集团股份有限公司可转换公司债券回售有关事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from the sponsoring institution (中航证券有限公司) regarding the conditional put-back (回售) rights of convertible bonds issued by 健帆生物科技集团股份有限公司. It references regulatory rules related to convertible bonds, issuance approvals, bond terms, put-back conditions, pricing, procedures, and payment schedules. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a formal audit or verification opinion related to a specific financial instrument issuance and its compliance with regulations. This fits the definition of an Audit Report / Information (AR), which includes applied accounting principles and results of internal or regulatory checks excluding full annual reports. The document length is 3130 characters, which is consistent with a standalone audit or verification report rather than a full annual or interim report. Q3 2025
2025-08-01 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.